GDI1 Antibody
Description
Introduction to GDI1 Antibody
GDI1 antibodies are immunological reagents designed to detect and analyze the GDI1 protein, encoded by the GDI1 gene located on the X chromosome. These antibodies are widely used in research to investigate GDI1's regulatory functions in Rab GTPase activity, its role in neurological disorders, and its implications in cancer biology .
Research Applications
GDI1 antibodies are validated for multiple techniques:
Colorectal Cancer (CRC) Prognosis
-
mRNA Overexpression: High GDI1 levels correlate with poor survival (HR = 0.63; 95% CI 0.35–1.14, p = 0.1137) .
-
Chemotherapy Response: Low GDI1 subgroups show better outcomes post-chemotherapy (HR = 0.22; 95% CI 0.09–0.56, p = 0.0003) .
-
Protein Validation: Cytoplasmic/membrane GDI1 expression predicts CRC aggressiveness .
Neurological Disorders
Future Directions
-
Therapeutic Targeting: Explore GDI1 inhibition to modulate Rab activity in cancer or neurological diseases .
-
Biomarker Validation: Expand clinical studies to validate GDI1 as a prognostic marker across cancer types .
-
Mechanistic Studies: Elucidate GDI1’s role in synaptic vesicle recycling and neurodegeneration .
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- SCN1, also known as AtRhoGDI1, is a RhoGTPase GDP dissociation inhibitor that spatially restricts the sites of growth to a single point on the trichoblast. [SCN1] PMID: 16355224
